NewGenIvf Group (NASDAQ:NIVF) & Medpace (NASDAQ:MEDP) Critical Contrast

Medpace (NASDAQ:MEDP) and NewGenIvf Group (NASDAQ:NIVF) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

Earnings & Valuation

This table compares Medpace and NewGenIvf Group”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53 billion	5.01	$451.12 million	$15.30	29.22
NewGenIvf Group	$5.43 million	0.14	-$520,000.00	N/A	N/A

Medpace has higher revenue and earnings than NewGenIvf Group.

Analyst Ratings

This is a summary of current recommendations for Medpace and NewGenIvf Group, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	2	8	4	0	2.14
NewGenIvf Group	1	0	0	0	1.00

Medpace currently has a consensus target price of $483.45, suggesting a potential upside of 8.13%. Given Medpace’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Medpace is more favorable than NewGenIvf Group.

Insider & Institutional Ownership

78.0% of Medpace shares are owned by institutional investors. Comparatively, 66.2% of NewGenIvf Group shares are owned by institutional investors. 20.3% of Medpace shares are owned by company insiders. Comparatively, 31.8% of NewGenIvf Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Medpace and NewGenIvf Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medpace	17.83%	118.82%	25.07%
NewGenIvf Group	N/A	N/A	N/A

Risk and Volatility

Medpace has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, NewGenIvf Group has a beta of -0.03, indicating that its share price is 103% less volatile than the S&P 500.

Summary

Medpace beats NewGenIvf Group on 11 of the 12 factors compared between the two stocks.

About Medpace

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

About NewGenIvf Group

NewGenIVF Group Ltd. operates as an assisted reproductive services provider. It focuses on providing fertility treatments to fulfil the dreams of building families. The firm offers in-vitro fertilization treatment service, comprising traditional IVF and egg donation, and surrogacy and ancillary caring services. The company was founded by Siu Wing Fung and Fong Hei Yue on January 16, 2019 and is headquartered in Bangkok, Thailand.